Skin cancers

Neoadjuvant immunotherapy: towards a new standard of care in melanoma

The very encouraging responses to neoadjuvant immunotherapy in melanoma trials are unparalleled and promise a new standard of care in the future, Australian cancer clinicians say. Speaking at the 2021 Clinical Oncology Society of Australia (COSA) ASM, Dr Elizabeth Ahern said that while both adjuvant and neoadjuvant treatment are given with the intention to improve ...

Already a member?

Login to keep reading.

© 2021 the limbic